| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ANXA2 |
| Uniprot No | P07355 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-339aa |
| 氨基酸序列 | STVHEILCKLSLEGDHSTPPSAYGSVKAYTNFDAERDALNIETAIKTKGV DEVTIVNILTNRSNAQRQDIAFAYQRRTKKELASALKSALSGHLETVILG LLKTPAQYDASELKASMKGLGTDEDSLIEIICSRTNQELQEINRVYKEMY KTDLEKDIISDTSGDFRKLMVALAKGRRAEDGSVIDYELIDQDARDLYDA GVKRKGTDVPKWISIMTERSVPHLQKVFDRYKSYSPYDMLESIRKEVKGD LENAFLNLVQCIQNKPLYFADRLYDSMKGKGTRDKVLIRIMVSRSEVDML KIRSEFKRKYGKSLYYYIQQDTKGDYQKALLYLCGGDD |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ANXA2重组蛋白的3篇代表性文献(内容基于公开研究整理，非真实文献)：
---
1. **文献名称**：*Recombinant ANXA2 protein regulates endothelial cell proliferation and angiogenesis in vitro*
**作者**：Smith J, et al.
**摘要**：本研究通过表达并纯化重组ANXA2蛋白，发现其能通过结合细胞表面受体(如VEGFR2)激活MAPK信号通路，促进内皮细胞增殖和血管生成，提示ANXA2在肿瘤微环境中的潜在作用。
2. **文献名称**：*Structural analysis of ANXA2-S100A10 heterotetramer and its role in membrane fusion*
**作者**：Li X, et al.
**摘要**：利用重组ANXA2与S100A10蛋白复合物的晶体结构解析，揭示了二者形成的异源四聚体如何通过钙离子依赖性机制参与细胞膜修复及胞吐过程，为病理状态下膜动力学异常提供分子基础。
3. **文献名称**：*ANXA2 facilitates influenza A virus entry by interacting with viral hemagglutinin*
**作者**：Wang Y, et al.
**摘要**：通过体外重组ANXA2蛋白实验，证明其能与流感病毒血凝素(HA)结合，促进病毒内吞和核内体释放，敲低ANXA2显著抑制病毒侵染，表明其作为抗病毒治疗靶点的潜力。
---
以上文献摘要概括了ANXA2在细胞信号、结构功能及病原互作等方向的研究，实际引用时需查询具体论文数据库(如PubMed)获取真实信息。
Annexin A2 (ANXA2) is a calcium-dependent phospholipid-binding protein belonging to the annexin superfamily, which plays diverse roles in membrane organization, intracellular signaling, and vesicle trafficking. It exists as a monomer or heterotetrameric complex with S100A10 (p11), regulating processes like cell proliferation, differentiation, and extracellular matrix remodeling. ANXA2 is implicated in pathological conditions, including cancer metastasis, cardiovascular diseases, and autoimmune disorders, due to its involvement in fibrinolytic activity, angiogenesis, and viral entry mechanisms.
Recombinant ANXA2 protein is typically produced using bacterial (e.g., *E. coli*) or eukaryotic expression systems to ensure proper folding and post-translational modifications. The recombinant form retains functional domains, including the N-terminal domain mediating protein interactions and the conserved C-terminal core for membrane association. Researchers utilize it to study ANXA2’s role in cancer cell invasion by facilitating plasminogen activation, its contribution to endothelial cell migration during angiogenesis, and its interaction with viral proteins (e.g., HIV-1 gp41). In neurodegenerative diseases, ANXA2 is linked to amyloid-β clearance, making its recombinant form valuable for therapeutic exploration.
Additionally, recombinant ANXA2 serves as an antigen in immunoassays to detect autoantibodies in autoimmune diseases like antiphospholipid syndrome. Its biochemical properties are analyzed to develop inhibitors targeting ANXA2-S100A10 interactions or membrane-binding sites, offering potential therapeutic strategies. Despite its versatility, challenges remain in understanding context-dependent functions, as ANXA2 exhibits dual roles (pro- and anti-tumor) depending on cellular localization and binding partners. Ongoing studies aim to clarify these mechanisms using recombinant protein-based models, advancing its application in diagnostics and targeted therapies.
×
